Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Gene

ERK

2 articles · Resources: NCBI Gene, OncoKB

Clinical

Reversal of KRAS G12D inhibitor resistance by nimotuzumab via MEK/ERK-mediated unfolded protein response in pancreatic cancer

Xue S, Xu H, Ma J, et al.

Cancer letters

This study investigates resistance mechanisms to KRAS G12D inhibitors, such as HRS-4642, in pancreatic ductal adenocarcinoma (PDAC). Researchers identified the reactivation of the unfolded protein response (UPR) via the MEK/ERK pathway as a key mechanism of acquired resistance, observed in vitro, in vivo, and in patients. To overcome this resistance, a combination therapy with nimotuzumab was tested, demonstrating strong synergy and resistance reversal. Nimotuzumab sustained the suppression of the MEK/ERK/UPR axis while exacerbating endoplasmic reticulum stress, leading to profound cellular damage. These findings suggest a promising combined strategy for PDAC patients harboring KRAS G12D mutations.

Molecular biology

Invasion/metastasis-related differentially methylated genes predict prognosis in diffuse gliomas

Zhang S, Sun Z, Jiang S, et al.

Journal of neuro-oncology

This study identified invasion/metastasis-related differentially methylated genes (DMGs) with prognostic relevance in diffuse gliomas. A risk model was constructed using two marker genes, ERRFI1 and MYO1G, demonstrating robust predictive performance in both training and independent validation cohorts. Patients classified as high-risk exhibited worse overall survival and altered immune infiltration. In vitro functional validation showed that knockdown of ERRFI1 or MYO1G inhibited glioma cell proliferation, invasion, and migration, with potential involvement of the EGFR/MAPK/ERK pathway.